- Home
- CCEP vs TAK Comparison
CCEP vs TAK Comparison
Compare CCEP & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEP | TAK |
|---|---|---|
| Founded | 1986 | 1781 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3B | 55.1B |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CCEP | TAK |
|---|---|---|
| Price | $107.01 | $17.41 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $104.33 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 4.2M |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | 2.48% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.86 | $0.16 |
| Revenue Next Year | $3.79 | $1.22 |
| P/E Ratio | ★ $20.93 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.66 | $12.99 |
| 52 Week High | $113.67 | $18.90 |
Technical Indicators
Market Signals| Indicator | CCEP | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 57.99 |
| Support Level | $102.60 | $16.23 |
| Resistance Level | $109.28 | $17.83 |
| Average True Range (ATR) | 2.34 | 0.25 |
| MACD | -0.54 | 0.00 |
| Stochastic Oscillator | 40.61 | 72.22 |
Price Performance
Historical ComparisonAbout CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.